

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number
WO 03/061680 A2

(51) International Patent Classification⁷: **A61K 38/00**

(21) International Application Number: PCT/CH03/00056

(22) International Filing Date: 23 January 2003 (23.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02001839.6 26 January 2002 (26.01.2002) EP

(71) Applicant (for all designated States except US): **MONDO-BIOTECH SA** [CH/CH]; Via Pasquée 23, CH-6925 Gentilino (CH).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BEVEC, Dorian** [DE/CH]; Via Pasquée 23, CH-6925 Gentilino (CH).

(74) Agent: **SALGO, R.C.**; Rütistrasse 103, CH-8636 Wald (CH).

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, SL, TN, TT, UA, US, UZ, VC, VN, YU, ZA.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF COMPOUNDS HAVING THE BIOLOGICAL ACTIVITY OF VASOACTIVE INTESTINAL PEPTIDE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

(57) Abstract: The present invention relates to the use of peptides and pharmaceutical compositions containing said peptides, that are highly biologically and pharmacologically active as therapeutic drugs for the treatment of diseases related to chronic obstructive pulmonary disease (COPD) which is preferably not correlated to pulmonary hypertension symptoms. Furthermore, the invention discloses the use of said peptides for another lung disease which is acute (adult) respiratory distress syndrome (ARDS). It could be shown that the known naturally occurring peptides "vasoactive intestinal peptide (VIP)" and "pituitary adenylate cyclase-activating polypeptide (PACAP)" as well as analogues or derivatives of VIP and PACAP can be successfully used for the treatment of said diseases.

WO 03/061680 A2